Mavacoxib (trade name Trocoxil) is a veterinary drug used to treat pain and inflammation in dogs with degenerative joint disease. It acts as a COX-2 inhibitor.
Mavacoxib, along with several other COX-2 selective inhibitors, including celecoxib, valdecoxib, and parecoxib, were discovered by a team at the Searle division of Monsanto led by John Talley.
Jun 23 2003References
European Public Assessment Report (EPAR): Trocoxil Archived 17 March 2018 at the Wayback Machine, European Medicines Agency http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/veterinary/000132/WC500069275.pdf ↩
Cox SR, Lesman SP, Boucher JF, Krautmann MJ, Hummel BD, Savides M, et al. (October 2010). "The pharmacokinetics of mavacoxib, a long-acting COX-2 inhibitor, in young adult laboratory dogs". Journal of Veterinary Pharmacology and Therapeutics. 33 (5): 461–70. doi:10.1111/j.1365-2885.2010.01165.x. PMID 20840390.{{cite journal}}: CS1 maint: overridden setting (link) /wiki/Doi_(identifier) ↩
Langreth R (23 June 2003). "The Chemical Cobbler". Forbes.{{cite news}}: CS1 maint: overridden setting (link) https://www.forbes.com/global/2003/0623/050.html ↩
"Dr. John Talley: 2001 St. Louis Awardee" (PDF). Chemical Bond. 52 (5). St. Louis Section, American Chemical Society: 2. May 2001. Archived from the original (PDF) on 15 April 2018. https://web.archive.org/web/20180415180802/http://www.stlacs.org/Bonds/2001May.pdf ↩